• Blueprint for Proposal Reviews (RFPs & RFQs): Biotech & CDMO Strategies in the Digital Competitive Era
    By Published On: October 15, 2024Categories:

    The Request for Proposal (RFP) process is not just a formality, but a crucial step in establishing effective collaborations between biotechs and Contract Development and Manufacturing Organizations (CDMOs).

  • Transforming CDMOs through Innovation, Customer-Centricity, and Service Excellence
    By Published On: October 10, 2024Categories:

    CDMOs play a pivotal role in accelerating drug development and manufacturing processes.

  • Biotech Innovation: Guiding points on Fast-to-Clinic / Fast-to-Market Strategies for Biotech & CDMOs
    By Published On: October 10, 2024Categories:

    In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs.

  • Antibody Drug Conjugates (ADCs) Guiding points on Seamlessly Integrating Development, Manufacturing, Safety, and Supply Chain Excellence
    By Published On: October 10, 2024Categories:

    Antibody-drug conjugates (ADCs) are pioneering biologics that merge antibodies' specificity with small molecules' potency.

  • Driving Biotech Innovation
    By Published On: September 14, 2024Categories:

    This article explores biotech's fast-to-clinic/market strategy, focusing on the role of CDMOs.

  • ADCs and their Drug Development Process
    By Published On: September 14, 2024Categories:

    One of the fastest-growing modalities in the pharmaceutical industry, antibody-drug conjugates (ADCs), combines a targeted antibody with a cytotoxic payload to offer numerous therapeutic benefits.

  • Fast-to-Clinic, Fast-to-Market in Biotech Innovation: Optimizing Chemistry Manufacturing & Controls (CMC) Excellence for Clinical and Commercial Success 2024
    By Published On: July 24, 2024Categories:

    In the emerging world of biotech innovation, the fast-to-clinic/market strategy has emerged as a critical “mantra” for biotech, investors, and CDMOs. This approach addresses the escalating costs and complexities of research and development by streamlining the path from concept to clinical trials and, ultimately, to market.

  • The ABC of ADCs (Antibody-Drug Conjugates): A Comprehensive Review of Technical, Regulatory, and Clinical Challenges 2023
    By Published On: October 27, 2023Categories:

    Over the past several decades, there has been a significant surge in the development of Antibody-Drug Conjugates (ADCs). Designing an ideal ADC presents a multifaceted challenge, requiring the precise orchestration of various elements such as antigens, antibodies, linkers, and payloads.

  • Antibody-Drug Conjugates (ADCs): Navigating Four Pillars of Safety, Development, Supply Chain and Manufacturing Excellence 2023
    By Published On: October 19, 2023Categories:

    Antibody-drug conjugates (ADCs) are pioneering biologics that merge antibodies’ specificity with small molecules’ potency. With a handful of FDA-approved ADCs in the market and many under development, ADCs are poised to revolutionize therapeutics.

  • Transforming Molecules into Medicines: Role of CDMOS in Phase-Appropriate Technology Transfers in Advancing Pharmaceutical Innovation 2023
    By Published On: June 15, 2023Categories:

    CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing.